In a lab in Indianapolis, a team led by Reuben Kapur and Santhosh K. Pasupuleti has uncovered a trio of proteins quietly fueling one of the rarest and most aggressive childhood leukemias—juvenile myelomonocytic leukemia (JMML). For families facing this devastating diagnosis, where just one to two children per million are affected each year, the discovery offers a glimmer of hope not just in a new treatment path, but in medicines that already exist. Published in the journal Blood, the research reveals how inflammatory proteins—IL-17A, PTGS2 (also known as COX-2), and NLRP3—increase cancer growth while simultaneously weakening the immune system, exhausting T cells, and expanding immune-suppressive cells. This double-edged mechanism helps explain why current treatments, primarily bone marrow transplants, often fail, especially in high-risk cases.
The breakthrough came when the team tested existing drugs in mouse models and human patient samples. They found that blocking this inflammatory cascade didn’t just slow leukemia progression—it reversed key markers of disease. Celecoxib, a widely available anti-inflammatory drug commonly used for arthritis, and secukinumab, an FDA-approved antibody that targets IL-17A and is already prescribed for pediatric inflammatory conditions, showed strong potential. When combined with MEK inhibitors, a class of cancer drugs already in use, the treatment strategy significantly reduced leukemia burden and improved survival rates.
"We showed that blocking this inflammatory pathway reduced leukemia burden, restored immune function, decreased abnormal myeloid cell growth and significantly improved survival," said Pasupuleti, assistant research professor of pediatrics at Indiana University School of Medicine and first author of the study. That statement isn’t just a scientific observation—it’s a roadmap. Because chronic inflammation plays a role in many cancers, this approach could extend beyond JMML to other leukemias and solid tumors driven by similar immune disruptions.
What makes this discovery especially urgent is the lack of effective therapies for JMML’s most aggressive forms. With bone marrow transplants failing in many cases and relapse rates high, new strategies are desperately needed. The team now plans further preclinical studies to pinpoint which cells are most vulnerable and to refine the optimal drug combination. They’re also exploring whether a simple blood test measuring levels of IL-17A, PTGS2, and NLRP3 could help identify which children would respond best—turning biomarkers into a precision medicine tool.
For a disease as rare as JMML, progress is often slow. But here, researchers are not starting from scratch. By repurposing safe, approved drugs, they’re accelerating the path to clinical trials. As Kapur, director of the IU School of Medicine Herman B Wells Center for Pediatric Research, noted, the implications may stretch far beyond one childhood cancer. In the fight against cancer-fueled inflammation, this could be a turning point—one built not on distant futures, but on medicines already in medicine cabinets.